long intergenic non-protein coding RNA 1927Genealiases: []
Q-omics provides the consensus-scored LINC01927 profile across patient tissues and cancer cell-line models. LINC01927 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01927 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, LINC01927 RNA expression shows 10,202 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUAD, and TGCT as cancer lineages where LINC01927 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01927 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01927 survival associations across molecular data types. LINC01927 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01927 RNA expression–survival associations across cancer types. High LINC01927 expression shows unfavorable associations in KIRP, LGG and UVM, but favorable associations in HNSC, UCEC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01927 RNA expression.
This table summarizes LINC01927 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01927. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01927 shows lower tumor expression in LUAD, LUSC, KIRP, LIHC, THCA and COAD. The LUAD box plot shows higher LINC01927 RNA expression in normal versus tumor tissue (log2 FC = −0.553, t-test p < 0.001).
This table shows molecular features associated with LINC01927 in patient tissues and cancer cell lines. In patient samples, LINC01927 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
